{'fraction_non_alphanumeric': 0.04036326942482341, 'fraction_numerical': 0.02119071644803229, 'mean_word_length': 5.238993710691824, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Linear growth of very young asthmatic children treated with high‐dose nebulized budesonide

The aim of this open study was to observe linear growth in young children with asthma treated with nebulized budesonide. Infants and young children (< 3 years old) with severe uncontrolled asthma were studied. They were treated with nebulized budesonide (1‐4mgday‐1) and treated for at least 6 months. Height standard deviation scores (HtSDS) were measured before (“pre‐measurements”) immediately prior to commencing nebulized budesonide therapy (baseline) and after at least 6 months of therapy (“post‐measurements”). The mean HtSDS score at pretreatment was ‐0.21 and at baseline had fallen further to ‐0.46. The mean HtSDS increased to ‐0.17 when the post‐measurements were made (p= 0.035) after at least 6 months of nebulized budesonide therapy. Treatment with nebulized budesonide for longer than 6 months in very young children with severe asthma was not associated with reduced linear growth.